Celyad Oncology SA (CYADB.XC)
| Previous close | 0.65 |
| Open | N/A |
| Bid | 0.63 x N/A |
| Ask | 0.66 x N/A |
| Day's range | 0.65 - 0.65 |
| 52-week range | 0.65 - 6.67 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 176.92M |
| Beta (5Y monthly) | 1.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.23 |
| Earnings date | 27 Jun 2024 - 28 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireCelyad Oncology Reports Full Year 2023 Financial Results and Recent Business Highlights
MONT-SAINT-GUIBERT, Belgium, April 04, 2024--Regulatory News: Celyad Oncology (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the "Company"), today announces its financial results for the fiscal year 2023 ended December 31, 2023, and provides a business update.
GlobeNewswireCelyad Oncology announces intention to terminate SEC reporting obligations
MONT-SAINT-GUIBERT, Belgium, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) announces that it will voluntarily file a Form 15F with the United States Securities and Exchange Commission (the “SEC”) to terminate its SEC reporting obligations under Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Upon filing of the Form 15F, the Company’s SEC reporting obligations will be immediately s
- GlobeNewswire
Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook
Three main pillars to unlock the potential of proprietary technology platforms and intellectual property: A proprietary non-gene editing technology platform based on multiplexing of short hairpin ribonucleic acid (shRNAs)-derived sequences to broaden the capacities of CAR-TsDifferentiated targets to widen the range of indications and the development of multispecific CARs to overcome the main limitations of current CAR-T therapiesA robust and broad Intellectual Property (IP) portfolio MONT-SAINT-
